Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q3 2020 · 10-Q
Revenue$29.81K$29.81K−36.0% vs Q3 2019 Net Income-$785.17K-$785.17KN/M vs Q3 2019 EPS Diluted-$0.14-$0.14N/M vs Q3 2019 Operating Income-$2,052,858N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-6886.7%−4984.6 pt vs Q3 2019
Net margin-2634.0%−413.6 pt vs Q3 2019
ended Sep 30, 2020 · filed Nov 16, 2020 · 47 d after period end